Fig. 2.

CP-870,893 prevents mortality induced by several B-cell lymphomas. a CP-870,893 was administered i.p. followed by the injection of 5 × 10⁶ Daudi cells (IV). Mortality was monitored for 50 days. The MST was 25 days for the anti-KLH group and 48 days for the animals treated with CP-870,893. The group size was 10 animals per group and the study is representative of 5 separate studies. b CP-870,893 was administered i.p. at the time of s.c. tumor challenge with the B-cell lymphoma Daudi. Tumor size is represented in mm². Each data point is the mean ± the SE for 5 animals per group and is representative of 3 separate experiments. c CP-870,893 was administered i.p. at the time of s.c. tumor challenge with the B-cell lymphoma Jijoye. Each data point refers to the mean tumor size in mm² ± the SE for 5 animals per group. The study is representative of 3 separate studies